Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Jamaica
(0/week)
Netherlands Antilles
(0/week)
View all
(0/week)
News
United States
(1405/week)
Manufacturing
(646/week)
Energy
(481/week)
Technology
(1196/week)
Other Manufacturing
(460/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Angiotensin II receptor antagonists
Nov 17, 2019
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Mar 12, 2019
FDA approves a new generic valsartan
Mar 09, 2019
Information Update - Multiple Losartan-containing drugs voluntarily recalled because of potential for nitrosamine impurity
Mar 01, 2019
FDA provides update on its ongoing investigation into ARB drug products; reports on finding of a new nitrosamine impurity in certain lots of losartan and product recall
Nov 28, 2018
Information Update - Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity
Nov 08, 2018
Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)
Sep 13, 2018
FDA provides update on its ongoing investigation into valsartan products; and reports on the finding of an additional impurity identified in one firm's already recalled products
Sep 06, 2018
Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to product/label mix-up
Aug 31, 2018
FDA announces voluntary recall of Montelukast tablets by Camber Pharmaceuticals due to incorrect drug in bottles
Aug 30, 2018
Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research on FDA's ongoing investigation into valsartan impurities and recalls and an update on FDA's current findings
Aug 20, 2018
/R E P E A T -- Information Update - Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution/
Jul 13, 2018
FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity
Jul 10, 2018
Update - Advisory - Several drugs containing valsartan being recalled due to contamination with a potential carcinogen
Jul 10, 2018
Investigation Report on the Chinese Valsartan (Diovan) Market 2018-2022: Sales, Market Shares, Prices and Prospects
Jul 09, 2018
Advisory - Several drugs containing valsartan being recalled due to contamination with a potential carcinogen
Aug 01, 2017
Daiichi Sankyo Announces Settlement Agreement on U.S. Products Liability Litigation
Latest News
Aug 14, 2025
Spartan Emergency Response Breaks Ground on $20 Million Facility Expansion to Increase Production
Aug 14, 2025
Alliance Resource Partners, L.P. Announces the Promotion of Jesse M. Parrish to Sr. Vice President and Chief...
Aug 14, 2025
KBRA Downgrades Pennsylvania Turnpike Commission Oil Franchise Tax Senior Revenue Bonds to AA- and...
Aug 14, 2025
Kontrol Technologies Announces Second Quarter 2025 Financial Results
Aug 14, 2025
Halliburton Announces Dividend
Aug 14, 2025
Carlisle Companies Announces Pricing of Senior Notes Offering
Aug 14, 2025
Bioretec Ltd's Half-year report 2025: Strong support for future growth from a successful rights issue
Aug 14, 2025
Parents Urged to Make Kids' Bedtime Screen-Free as National Campaign Launches with NYC Flash Mob
View all News
Agenda
30
September
Portugal
Troia, Portugal
Seabed Security, 30 September - 01 October 2025, Troia, Portugal
Seabed Security | 30 September - 01 October 2025 | Troia, Portugal Defence iQ Announces Inaugural Seabed Security...
23
September
United Kingdom
London, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
View All Events